Award recordCONTRACT

AVKARE LLC

PIID 36E79726D0002· VA Staff Offices· NAC PHARMACEUTICALS (36E797)· 6505 · DRUGS AND BIOLOGICALS· FY2026· $0 net obligations· UEI SFPGXE6XPS93· TN

Description

MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION

Base award description: NEW AWARD FOR METFORMIN HYDROCHLORIDE (HCL) 24HR SUSTAINED ACTION (SA) TABLETS PERIOD IS DECEMBER 30, 2025 - DECEMBER 29, 2026 WITH FOUR ONE-YEAR OPTIONS.

First action · last action
2025-10-30 · 2026-08-27
Transactions
3
First transaction's obligation
$0
Base + all options value (sum of deltas)
$90,709,478
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 3 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1$0Base award · 2025-10-30 · this action $0 · running total $0Modification P00001 · 2025-12-10 · this action $0 · running total $0Modification P00002 · 2026-08-27 · this action $0 · running total $0
  • Base2025-10-30+$0= $0
  • Mod P000012025-12-10+$0= $0
  • Mod P000022026-08-27+$0= $0
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2025-10-30+$0$0NEW AWARD FOR METFORMIN HYDROCHLORIDE (HCL) 24HR SUSTAINED ACTION (SA) TABLETS PERIOD IS DECEMBER 30, 2025 - D…
Mod P00001· ADD SUBCONTRACTING PLAN2025-12-10+$0$0MODIFICATION TO AVKARE CONTRACT TO INCORPORATE 2026 SUBCONTRACTING PLAN FOR METFORMIN HYDROCHLORIDE (HCL) 24HR…
Mod P00002· OTHER ADMINISTRATIVE ACTION2026-08-27+$0$0MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI SFPGXE6XPS93)

AwardOffice · PSC / listingNet obligationsFY
36E79726D0036NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79726D0031NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79725D0046NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36E79725D0027NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36E79725D0020NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36E79725D0019NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025

Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)

AwardRecipientOfficeNet obligationsFY
36E79726A0025CHIESI USA INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0024NEUROTECH PHARMACEUTICALS, INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0023TAKEDA PHARMACEUTICALS AMERICA, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726D0041GOLDEN STATE MEDICAL SUPPLY, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0022AURINIA PHARMA US INCNAC PHARMACEUTICALS (36E797)$0FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79726D0002_3600 · retrieved 2026-09-26.